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Abstract
Background: Red blood cell (RBC) polymorphisms are common in malaria
endemic regions and are known to protect against severe forms of the disease.
Therefore, it is important to screen for these polymorphisms in drugs or vaccines
efficacy trials. This study was undertaken to evaluate associations between clinical
malaria and RBC polymorphisms to assess biological interactions that may be
necessary for consideration when designing clinical trials.
Method: In a cross-sectional study of 341 febrile children less than five years of
age, associations between clinical malaria and common RBC polymorphisms
including the sickle cell gene and G6PD deficiency was evaluated between
November 2008 and June 2009 in the middle belt of Ghana, Kintampo. G6PD
deficiency was determined by quantitative methods whiles haemoglobin variants
were determined by haemoglobin titan gel electrophoresis. Blood smears were
stained with Giemsa and parasite densities were determined microscopically.
Results: The prevalence of clinical malarial among the enrolled children was
31.9%. The frequency of G6PD deficiency was 19.0% and that for the haemoglobin
variants were 74.7%, 14.7%, 9.1%, 0.9% respectively for HbAA, HbAC, HbAS and
HbSS. In Multivariate regression analysis, children with the HbAS genotype had
79% lower risk of malaria infection compared to those with the HbAA genotypes
(OR50.21, 95% CI: 0.06–0.73, p50.01). HbAC genotype was not significantly
associated with malaria infection relative to the HbAA genotype (OR50.70, 95% CI:
0.35–1.42, p50.33). G6PD deficient subgroup had a marginally increased risk of
malaria infection compared to the G6PD normal subgroup (OR51.76, 95% CI:
0.98–3.16, p50.06).
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Conclusion: These results confirm previous findings showing a protective effect of
sickle cell trait on clinical malaria infection. However, G6PD deficiency was
associated with a marginal increase in susceptibility to clinical malaria compared to
children without G6PD deficiency.
Introduction
It is estimated that there are about 216 million cases of malaria each year and
about 655, 000 deaths worldwide [1]. Over 91% of these deaths occur in sub-
Saharan Africa [1, 2]. Children under the age of five years are the most vulnerable
to malaria morbidity and mortality due to their immune-naı¨ve status [3].
However, until the age of about six months, such children are protected from
malaria by maternal antibodies [4, 5]. Susceptibility to malaria increases
substantially as maternal protection wanes [5, 6].
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and haemoglobins S
(HbS) are common genetic disorders in sub-Sahara Africa [7]. Glucose-6-
phosphate dehydrogenase deficiency is a X-linked genetic disorder though most
deficient people are asymptomatic [8]. Sickle cell trait (HbAS) which is clinically
silent occurs when an individual inherits one gene copy of mutated haemoglobin
(S) gene and one gene copy of the normal haemoglobin (A) gene. Sickle cell
anaemia (HbSS) on the other hand is clinically severe and it results when two
copies of mutated haemoglobin genes are inherited but both conditions are
caused by haemoglobin S.
Sickle cell trait and other red blood cell2related genetic factors, such as alpha-
thalassaemia, as well as metabolic abnormalities including glucose-6-phosphate
dehydrogenase (G6PD) deficiency have also been associated with protection
against clinical malaria [9, 10]. The degree of risk and protection against malaria
conferred by genetic factors may depend on the prevalence of other co-infections.
The prevalence of G6PD deficiency in Ghana is estimated to be about 12%
among pregnant women [11] and 20% G6PD prevalence has been recorded
among African children with malaria [12]. About 2% of Ghanaian newborns have
either sickle cell trait or disease [13] and the prevalence exceeds 25% in some areas
in Africa [7]. G6PD deficiency and sickle cell disease are important causes of
morbidity and mortality in Ghana [13]. The extent of risk or protection from
malaria conferred by these two disorders, in the era of the changing patterns of
malaria in Ghana needs to be investigated.
The Kintampo North Municipality lies within the forest-savannah transition
belt of Ghana and has high levels of malaria transmission [14]. Transmission in
the Kintampo area is all year round with parasite prevalence estimated to be
greater than 50% in children. Annual entomological inoculation rates estimated in
2004 and repeated in 2005 were 269 and 231 infective bites per person per year
respectively [15]. The area is one of the few sites in Ghana where vaccines and
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drugs clinical interventions aimed at reducing malaria incidence are evaluated.
This study was carried out to determine the associations between G6PD deficiency
and sickle cell haemoglobinopathy and clinical malaria in the Municipality.
Evidence of a significant effect would provide a rationale for routine testing of red
cell polymorphisms in malaria clinical trials in the area.
Materials and Methods
Ethical statement
Ethical approval of the study was given by the Kintampo Health Research Centre
Institutional Ethics Committee. At enrolment, the study objectives, risks, benefits
and procedures of the study were explained to all caregivers whose children
participated in the study to seek their written informed consent. Caregivers gave
written informed consent on behalf of participating children. All data collected are
kept in locked cabinets to ensure confidentiality and participants’ identity and
records were anonymized prior to analysis.
Subjects, Design and Sample Collection
This was a cross-sectional study, carried out at the Kintampo North Municipal
Hospital in the Brong Ahafo Region of Ghana from November 2008 to June 2009.
Children less than five years of age who reported of fever (i.e. measured axillary
temperature§37.5 C˚ or reported fever in 48 hours prior to hospital attendance)
and without symptoms of severe illness were enrolled. All enrolled children were
residents of the Kintampo North Municipality as per study inclusion criteria
where malaria transmission intensity is as high as 269 infective bites/person/year
and malaria parasite prevalence is .50% [14, 15].
Individual written informed consent was obtained from all caregivers prior to
enrolment. A study clinician initially took clinical history and carried out a
physical examination on all children irrespective of their disease condition, after
which blood samples were taken to test for malaria and host genotypes including
sickle cell. Recruitment into the study covered both the dry (November) and rainy
(June) seasons as the causes of fevers are not the same throughout the year and
each child was seen once at the outpatient department (OPD) without any follow
up visit. Any child diagnosed as having clinical malaria, defined as fever (i.e.
measured axillary temperature §37.5 C˚ or reported fever in 48 hours prior to
hospital attendance) plus a positive malaria blood smear, was treated with
artesunate/amodiaquine; other diseases diagnosed were treated according to the
Ghana Health Service (GHS) standard treatment guidelines. Information on
socio-demographic background was obtained through the use of a short
questionnaire. About 0.5 ml of finger-prick capillary blood was collected into
EDTAK2 anticoagulant tubes and used for the laboratory analysis at the Kintampo
Health Research Centre (KHRC) Clinical Laboratory. All blood samples were
obtained prior to treatment with artesunate/amodiaquine.
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Laboratory Procedures
G6PD activity
G6PD status was determined by the Randox quantitative method [16, 17]. Briefly,
0.2 ml of whole EDTA blood was washed three times with 2 ml aliquots of 0.9%
sodium chloride (NaCl) solution, centrifuged after each wash for 10 minutes at
3000rpm. The G6PD activity was determined using the washed erythrocytes and
the test method performed as described in the manufacturer’s instruction manual
(Randox Laboratory UK, BT29 4 QY). G6PD activities were expressed in U/g Hb
using the respective haemoglobin (g/dl) concentrations estimated with Micro 60
haematology analyzer (Horiba ABX, Montpellier, France).
The Randox quantitative method classifies the G6PD deficiency status of the
participants using a cut-off of 4.1 U/g Hb. All participants who measured enzyme
activity ,4.1 U/g Hb were classified as ‘‘Deficient’’ while those with enzyme
activity at 4.1 U/g Hb and above were ‘‘Normal’’. There was no classification for
partial deficiency. Two levels of quality controls, deficient (catalogue no. PD2617)
and normal levels (catalogue no. PD2618) were analyzed before the analysis of test
samples.
Haemoglobin concentration
Haemoglobin levels were determined using an ABX Micros 60 Haematology
analyzer (Horiba ABX, Montpellier, France). Scheduled external quality assess-
ment programme and daily internal quality controls were followed as quality
measures [18].
Haemoglobin Typing
The Helena electrophoresis system (Helena Biosciences Europe, Queensway
South, Gateshead Tyne and Wear NE II OSD) was used to electrophorese
haemolysates on Titan III cellulose acetate plates. The haemolysate was prepared
by mixing 1 part of whole blood to 3 parts Helena haemolysate reagent (0.005 M
EDTA with 0.01% potassium cyanide). Electrophoresis was performed at 350 V
for 25 minutes in a tris-EDTA/boric acid buffer (pH 8.4, ionic strength 0.035;
Helena). The electrophoretic procedure was performed as recommended by the
manufacturer. Helena Hemo quality controls provided and performed daily were
used as a maker for band identification.
Malaria parasitaemia
Thin and thick blood smears were prepared; the thick film was fixed in methanol
after drying and both thin/thick films stained with 10% Giemsa. The parasites
were counted against 200 leukocytes and then extrapolated to parasites per
microlitre of blood using the absolute leucocytes counts [14]. At least one
hundred thick film fields were examined before assigning a negative malaria
diagnosis. Two expert microscopists at the clinical laboratory of Kintampo Health
Research Centre who read each blood slide were blinded from each other’s
reading. All discordant readings were re-read by a third microscopist who was
blinded from the previous results.
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Data Management and Statistical Analysis
All the data were double-entered and verified for consistency using Microsoft
Access software version 2007. Final dataset was analyzed using STATA statistical
software (Version 11; StataCorp. TX USA). Proportions of categorical variables
such as bednet use or antimalarial use were compared using the x2-test and means
of continuous and normally distributed variables such as haemoglobin level were
compared using t-test (two-group comparison) and one way ANOVA (three-
group comparison). Statistical significance was set at p,0.05. Using a forward
selection method, a logistic regression model controlling for potential con-
founding variables such as antimalarial use and bed net use were used to
investigate the associations of G6PD and sickling status on clinical malaria. High
density malaria parasitaemia (HDP) was defined as malaria parasites§10,000/mL
of blood and severe anaemia was defined as haemoglobin concentration level less
than 6.0 g/dL.
Results
Demographic and clinical data
A total of 364 children were approached to be consented. Ninety-four percent
(341/364) were enrolled; 75% of the children enrolled into the study were above
11 months of age with remaining 25% either aged 11 months or below (Table 1).
About 53% of the children were males. Twenty-five percent of children had been
transfused with blood previously in more than 6 months prior to enrolment as a
result of earlier illness but children with recent blood transfusion(6 months or
less) were not enrolled (Table 1). Insecticide treated bed net (ITN) use was 69.2%
among the children enrolled (Table 1).
Frequency of Red Cell Polymorphisms
About one-fifth (19%) of the children were G6PD deficient (Table 2); 55.4% (36)
of G6PD deficient children were males. HbAS and HbAC genotypes were present
in 9.1% (31) and 14.7% (50) of 341 children respectively (Table 2). HbSC (1),
HbCC (1) and HbSS (3) genotypes occurred in less than 2% and were excluded
from the regression analysis. Twenty percent (50/255) of the children with HbAA
also had G6PD deficiency whilst 22% (11/50) of those with HbAC had G6PD
deficiency but only 13% (4/31) of HbAS individuals had G6PD deficiency.
Haemoglobin levels
Children with HbAC genotype had the highest mean haemoglobin (mHb) of
10.1 g/dL (95% CI: 9.0–10.5) and HbAS genotype had the lowest of 9.5 g/dL
(95% CI: 8.4–9.7) (Figure 1a). G6PD normal and deficient individuals had mHb
of 9.7 g/dL (95% CI: 9.1–11.1) and 9.6 g/dL (95% CI: 9.5–11.0) respectively
(Figure 1b). The mHb for G6PD deficient males and females were not significantly
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Table 1. Baseline characteristic of the study population.
Characteristic n(%)
Age group
0–11 mo* 84(24.6)
12–59 257(75.4)
Sex
male 180(52.8)
female 161(47.2)
Siblings
alive 321(94.1)
dead 20(5.9)
Blood transfusion
ever transfused
Transfusion Intervals** 84(24.6)
8–9 mo* 24(7.1)
10–16 mo 60(17.5)
never transfused 257(75.4)
No. of times transfused
once 52(61.9)
twice 20(23.8)
more than twice 12(4.3)
Bed net use
yes 234(69.2)
no 107(30.8)
*mo5age in months, n5total number of children, %5percentage of children.
**Interval of transfusion (in months) before enrolment.
Basic profiles of the study children as captured by questionnaire have been summarize. The age group, sex
and information of siblings and whether or not they have ever received blood transfusion and level of bed net
usage have been tabulated.
doi:10.1371/journal.pone.0112868.t001
Table 2. The prevalence of red blood cell polymorphisms.
Red Cell Polymorphisms n (%)
Haemoglobin variants HbAA 255 (74.7)
HbAS 31 (9.1)
HbAC 50 (14.7)
HbCC 1 (0.3)
HbSC 1 (0.3)
HbSS 3 (0.9)
G6PD variants Normal 276 (80.9)
Deficient 65 (19.1)
n5total number of children, %5percentage of children.
Children with different haemoglobin types as determined by electrophoresis have been presented in terms of number (n) and percentages (%) to show their
prevalence. HbAA5homozygous wild type genotype, HbAS5Heterozygote sickle cell haemoglobin, HbAC5heterozygote haemoglobin C,
HbSC5heterozygote haemoglobin S and C, HbCC5homozygote haemoglobin C, HbSS5homozygote haemoglobin S. G6PD variants has been
determined quantitatively using commercial kit from Randox Laboratory.
doi:10.1371/journal.pone.0112868.t002
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different (p50.40) but the mHb was significantly different among male and
female participants with G6PD normal (p5006). The proportion of severe
anaemia (haemoglobin concentration ,6 g/dL) for children in the entire cohort
was 2.6% (9/341). About 4.6% (3/65) of G6PD deficiency children had anaemia
but no child with the sickle cell trait had haemoglobin level less than 6.0 g/dL.
Red cell polymorphisms and clinical malaria
The overall prevalence of clinical malaria in the entire cohort of children was
31.9% (107/336). Univariate and multivariate models for clinical malaria infection
defined as the presence of fever and parasites have been summarized in Table 3. In
the multivariate regression analysis, children with HbAS genotypes were 79% less
likely to have clinical malaria as compared to those with HbAA genotype
(adjusted OR50.21, 95% CI: 0.06–0.73, p50.01). The risk of clinical malaria was
statistically not different among children with HbAC genotype relative to those
with HbAA genotype (adjusted OR50.70, 95% CI: 0.35–1.42, p50.33). The
G6PD deficient children were 1.76 times more likely to contract malaria as
compared to the G6PD normal subgroup, although this association was not
significant (adjusted OR51.76, 95% CI: 0.98–3.16, p50.06).
The risk of malaria in children who used bed nets was not significantly different
from those who did not use bed nets (adjusted OR51.17, 95% CI: 0.69–1.99,
p50.56). Children who did not use antimalarial had higher odds of contracting
clinical malaria as compared to children who used antimalarial (adjusted
OR52.70, 95% CI: 1.52–4.64, p50.001). Children aged 12–59 months were more
likely to have malaria as compared to children aged 0–11 months (adjusted
OR52.44, 95% CI: 1.30–4.56, p50.01). Among male children, the G6PD deficient
Figure 1. Mean Haemoglobin levels for children with different red cell polymorphisms. About 0.5 ml of capillary blood by finger prick was collected into
EDTAK2 anticoagulant tubes for each child and after performing the daily quality controls, the samples run on ABX Micro60 Haematology analyzer (ABX-
Horiba, France) to determine haemoglobin levels of children with different red cell polymorphism. Mean haemoglobin levels (mHb) were calculated for the
different red cell polymorphisms. mHb for the Haemoglobin variants (A) and G6PD variants (B) are indicated by the bars and their confidence intervals (CI)
indicated as lines.
doi:10.1371/journal.pone.0112868.g001
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children had higher odds of contracting malaria but this was not statistically
significant (adjusted OR51.20, 95% CI: 0.53–2.71, p50.657). Similarly among
females, children who were G6PD deficient were more likely to contract malaria as
compared to G6PD normal children (adjusted OR52.68, 95% CI: 1.10–6.52,
p50.031)(Table 3).
Red cell polymorphism and malaria parasite infection
The geometric mean parasite density (GMPD) observed among children with the
red cell polymorphism variants were: HbAC [65451/mL (95% CI: 22424–91039)],
HbAS [45045/mL; (95% CI: 5384–76899)], HbAA [43954/mL (95% CI: 30154–
64071)] (Figure 2a). There was no evidence of a significant relationship between
Table 3. Association between the red cell polymorphisms and clinical malaria.
Red Cell
Polymorphisms
Children with
clinical malaria
[n(%)]
Children without
clinical malaria
[n(%)]
Univariate
(unadjusted)
Odds ratio
(95% CI)
p-
value
Multivariate
(adjusted)
Odds ratio
(95% CI)
p-
value
Haemoglobin
variants
HbAA 90(84.1) 165(72.1) 1 – 1 –
HbAC 14(13.1) 36(15.7) 0.71(0.37–1.39) 0.321* 0.70(0.35–1.42) 0.356*
HbAS 3(2.8) 28(12.2) 0.20(0.06–0.66) 0.009* 0.21(0.06–0.73) 0.014*
G6PD
variants
Normal 80(74.8) 191(83.4) 1 – 1 –
Deficient 27(25.2) 38(16.6) 1.70(0.97–2.96) 0.063 1.76(0.98–3.16) 0.060
Bed net
use
Yes 72(67.9) 163(70.5) 1 – 1 –
No 34(32.1) 67(29.5) 1.13(0.69–1.86) 0.636 1.17(0.69–1.99) 0.562
Antimalarial
use
Yes 23(21.5) 91(39.7) 1 – 1 –
No 84(78.5) 138(60.3) 2.41(1.42–4.10) 0.001 2.70(1.52–4.64) 0.001
Gender Male 56(52.3) 122(53.3) 1 – 1 –
Female 51(47.7) 107(46.7) 1.04(0.66–1.64) 20.872 1.09(0.67–1.78) 20.725
Age(months) 0211 16(15.0) 68(29.7) 1 – 1 –
12259 91(85.00) 161(70.3) 2.40(1.32–4.39) 20.004 (2.44(1.30–4.56) 20.005
Male G6PD
deficient
Normal
Deficient
44(78.6) 98(80.3) 1 – 1 –
Normal
Deficient
12(21.4) 24(19.7) 1.11(0.51–2.43) 20.787 1.20(0.53–2.71) 20.657
Female G6PD
deficient
36(70.6) 93(86.9) 1 – 1 –
15(29.4) 14(13.1) 2.77(1.22–6.31) 20.015 2.68(1.10–6.52) 20.031
*Likelihood ratio p-value ,0.01.
n5number of children %5percentage of children CI5Confidence Interval.
Red cell polymorphisms were stratified according to the presence or absence of clinical malaria for analysis. Univariate and multivariate logistic regression
analyses were also performed. The odds ratio (OR) and p-values have been calculated to determine the level of significance of association between the red
cell polymorphisms and clinical malaria. Subgroup analysis for HbSC, HbCC and HbSS was not included due to small numbers obtained.
doi:10.1371/journal.pone.0112868.t003
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these red cell polymorphism and GMPD (one way ANOVA Bartlett’s test
Chi251.232, p50.54).
GMPD among G6PD deficient [29776/mL (95% CI: 14858–59672)] and G6PD
normal [53629/mL; (95% CI: 35931–80044)] children were similar (one way
ANOVA Bartlett’s test Chi250.162, p50.69) (Figure 2b).
High-density parasitaemia–HDP (parasites §10,000/mL of blood) was
observed in 16.8% (22/131) of HbAC and 3.1% (4/131) among the HbAS when
compared to 80.2% (105/131) of the HbAA subgroup (P50.007) (Figure 3a).
G6PD normal children with HDP was 77.9% (102/131) and that for the G6PD
deficient subgroup was 22.1% (29/131) (Figure 3b). However, the G6PD status
was not associated with high-density status (p50.30).
Discussion
Our results have demonstrated a reduction in malaria risk in children with the
sickle cell trait, an association that remained statistically significant in multivariate
regression analysis after controlling for bed net and antimalarial drug use.
Protection associated with HbAC was less significant as compared to HbAS
genotype. G6PD deficiency was however associated with marginal susceptibility
with clinical malaria.
Many studies globally [9, 19], have confirmed the protective role of sickle cell
trait in mild malaria disease, and so the relationship to clinical malaria found in
this study is not very surprising. The results obtained in this study support the
hypothesis that haemoglobin S offers selective advantage to carriers of HbAS
against clinical malaria (OR50.21, 95% CI: 0.06–0.73, p50.014), consistent with
similar studies in Kenya [9] and Gambia [20]. A number of possible biochemical
Figure 2. Geometric mean parasite density (GMPD) of children with the different red cell polymorphisms. Peripheral blood collected into EDTAK2
anticoagulant was used to prepare both thick and thin blood smears. Giemsa stained thick blood films were used for parasitological assessment and
parasite densities were calculated using the absolute leucocytes counts. The parasitaemia per ml of blood was calculated by using the WHO (1996) formula:
5(Number of parasites counted/WBC counted) 6 absolute WBC count/mL of participant. Parasite densities are reported as geometric means for
parasitaemic children with (A) showing haemoglobin variants, HbAA (n5167), HbAS (n510), HbAC (n537) and (B) G6PD normal (n5182), G6PD deficient
(n537) genotypes. Thus bars represent GMPD of individual red cell polymorphisms and their 95% confidence intervals represented as line.
doi:10.1371/journal.pone.0112868.g002
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and immune-mediated mechanisms have been proposed to be responsible for the
observed protection in HbAS individuals [21]. This include enhanced phagocy-
tosis by monocytes in HbAS infected red blood cells compared to Infected HbAA
and other cells due to increased presentation of opsonins including membrane
bound IgG and hemichromes [22]. The sickle cell trait is also reported to offer
protection in severe malaria through mechanisms such as impaired cytoadherence
and rosette forming [21, 23] and translocation of host microRNA into parasite
mRNA to reduce intra-erythrocytes growth [24].
Studies conducted in Nigeria [25] and Mali [26] that assessed the role of HbAC
and other haemoglobinopathies with respect to susceptibility to malaria have
documented contrasting results. Whilst the study in Nigeria [25] and one study in
Mali [26] indicated lack of protection of HbAC against clinical malaria, another
Malian study [27] showed evidence of HbAC protection against clinical malaria.
Our result showed a reduced malaria risk for HbAC phenotype in support of the
second Malian study [27] although this association was not statistically significant.
In a case-control study in Burkina Faso [28], HbAC was associated with 29%
reduction in risk of clinical malaria and 93% reduction in HbCC homozygote.
The level of protection by HbAC in the Burkina Faso study (OR 0.71; 95% CI:
0.58, 0.87) is comparable to the results obtained in this study (OR50.70; 95% CI:
0.35–1.42, p50.326). Inconsistencies in malaria-protective effect in many of the
structural haemoglobin variants may partly be a result of differences in study
designs and data analysis strategies used in the various investigations [29].
Nineteen percent (19%) of our study participants had G6PD deficiency, as
determined phenotypically. This is consistent with the prevalence of G6PD
Figure 3. Proportion of children with high density parasite (HDP) in the red cell polymorphisms. Children with high density parasite (HDP) defined as
§10,000 parasites/mL of blood was classified according to the red cell polymorphisms. This cut off value was used because of the likelihood of a clinical
attack when blood-stage parasites density exceeds 10,000 parasites/mL in endemic regions. Thick blood films were stained with Giemsa and the numbers of
malaria parasites were counted against leukocytes. The microscopist counted fields containing 200 leukocytes. If ,10 parasites were observed, the
counting continued up to 500 leukocytes. Where microscopists did the parasite counts in the thin film (against 2,000 red blood cells) as a result of heavy
parasitaemia (greater or equal to 100 parasites per thick smear high power field), parasites counted were recalculated with 200 WBC. Parasite densities
were calculated using absolute leukocytes/L of blood. (A), Bars indicate percentage of children with HDP in the haemoglobin variants subgroup and (B) bars
showing HDP in the G6PD variants subgroup.
doi:10.1371/journal.pone.0112868.g003
A Cross Sectional Study in Malaria Endemic Region
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deficiency assessed as part of a Phase III antimalarial drug trial in six African
countries including Ghana [12].
The protective role of G6PD deficiency in clinical malaria has also produced
conflicting results among various studies [25, 30]. Ruwende et al. found that
G6PD deficiency was associated with a 46–58% reduction in risk of malaria in
African children [31]. In some instances, G6PD deficient individuals infected with
Plasmodium falciparum were less ill than non–G6PD-deficient individuals [31].
The explanation could be that Plasmodium falciparum infection is usually not
lethal in G6PD deficient individuals [30] possibly because Plasmodium parasites
can proliferate less efficiently in their erythrocytes [32].
However it is still uncertain whether this advantage applies only to individuals
who are totally deficient of the G6PD enzyme. Guindo et al. (2007) found out that
partially deficient females suffer the same morbidity and mortality of Plasmodium
falciparum infection as non-deficient patients [33]. Mockenhaupt et al. (2003)
also found fewer Plasmodium falciparum infections in pregnant women with
partial G6PD deficiency [11]. In our study, the prevalence of Plasmodium
falciparum infection was 60% among the G6PD deficient subgroup and 42%
among G6PD normal subgroup with a weak evidence to support a statistical
difference (p50.03).
One of the most frequently cited field studies of the relationship between G6PD
deficiency and falciparum malaria is that of Bienzle et al. in Nigeria where 702
children aged 9 months to 6 years presenting at hospital with acute febrile illness
were assessed [34]. In that study, 66% of the children with G6PD deficiency were
found to have P. falciparum parasitaemia which is quite similar to what has been
observed in our study population [34].
Nevertheless variations in our findings with others reported elsewhere could
have resulted from differences in methods and populations involved. We were
unable to screen for additional co-infections, such as HIV-1 and bacteraemia,
believed to influence the course of malaria infection [35]. Other studies have been
performed as a community-based longitudinal investigation in which both
malaria morbidity and all-cause mortality were assessed in those children [10]. It
is possible that the children investigated in a cross-sectional study like ours, at the
hospital with their first episode of malaria may be clinically very distinct from
those children residing in the community that are presumably less ill and hence
such differences in results. We also think that G6PD deficient individuals with
malaria infection could easily haemolyse and thus, be brought to hospital for care
and this could account for high Plasmodium parasitisation in G6PD deficient
children.
Unlike insecticide treated bed net usage, children who had not been treated
with antimalarial drug were more likely to have clinical malaria. Therefore anti-
malaria use both as a preventive or curative treatment is likely to reduce
prevalence of the clinical malaria especially in children less than 5 years.
We could not examine the effects of three genotypes (HbCC, HbSS, and HbSC)
due to their small proportion and the statistical limitations associated. This
suggests the need for a bigger study in the area and under different levels of
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malaria transmission to better understand the patterns of protection or risk of
malaria that these other phenotypes may confer in this population.
We acknowledge some limitations of this study. First, we did not investigate the
role of thalassaemia in clinical malaria which could impact on the risk estimation
in this study. The prevalence of thalassaemia particularly a-thalassaemia is more
than 80% in parts of Africa, Southeast Asia and Melanesia [36]. Coinheritance of
the a-thalassemia, among individuals with sickle cell disease appears to be
protective against some sickle cell complications, such as acute chest syndrome,
anaemia, and cerebrovascular accidents [37]. However, a-thalassaemia interaction
with HbAS has been found to nullify the protective effect of both on malaria [38].
Secondly, the risk of malaria exposure at the individual participant level was not
assessed in this study. Malaria transmission intensity varies within microecological
zones [39, 40] and children who did not have malaria may not have been exposed
to malaria. However, in the study area, the force of infection is extremely high
(269 infective bites/person/year) [14] with little variance between communities
[15] and the incidence of clinical malaria among children is high [41]. Thirdly, the
risk of malaria infection which is relatively a common outcome in a malaria
endemic area has been estimated using odds ratios as an approximation for risk
ratios. This approach may have overestimated the odds ratios realised here.
Conclusion
From the perspective of protecting individuals from clinical malaria, HbAS
genotype has showed a clear advantage and superiority as compared with HbAC
and G6PD deficient genotypes in our study population. The biological
interactions between HbAS and clinical malaria has suggested the need to critically
look at HbAS as an innate host factor in randomized trials or observational
studies for detecting the effect of interventions, especially in areas of high HbAS
prevalence.
As millions of people are exposed to malaria annually, there is the need to
continually explore all possible associations that red cell polymorphisms may have
with disease susceptibility or protection when designing malaria intervention
programs.
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